The market for Positive Airway Pressure (PAP) Devices is projected to expand significantly, starting from a valuation of approximately US$ 6,291.58 million in 2023 and expected to reach around US$ 10,544.70 million by 2031. This growth represents a compound annual growth rate (CAGR) of 6.7% from 2023 to 2031. The increasing demand for these devices, coupled with a notable shift towards home healthcare solutions, is driving the expansion of the PAP devices market. However, the market faces challenges, particularly due to product recalls that can hinder growth. On a positive note, ongoing technological innovations in PAP devices are anticipated to introduce new trends in the market in the near future.
In 2023, North America emerged as the leading region in the PAP devices market. The United States stands out as the largest and fastest-growing market for these devices, expected to maintain its dominance throughout the forecast period. The growth of the PAP devices market in the US is fueled by the presence of advanced healthcare infrastructure, a rising incidence of sleep apnea disorders, and the introduction of innovative products by major market players. Companies like ResMed are at the forefront, offering a diverse range of devices for sleep apnea treatment, including the AirMini, AirSense 10 CPAP, and AirSense 10 Elite. ResMed is also involved in sponsoring various research initiatives aimed at improving sleep apnea treatment.
Moreover, the US market for PAP devices is set to grow further due to the increasing approval of advanced technological products. For example, in April 2024, researchers from the University of Cincinnati unveiled a novel technology named VortexPAP, which utilizes a unique airflow mechanism and offers various fitting options for users.
In Canada, the rising incidence of obstructive sleep apnea, particularly among the aging population, is driving the demand for PAP devices. According to the Conference Board of Canada, the proportion of seniors in the Canadian population is projected to increase from 16.9% in 2018 to 21.0% by 2028. Given that obstructive sleep apnea is prevalent among older adults, there is a significant need for PAP devices in Canada to manage this condition.
Additionally, both government and private entities are providing financial support to alleviate the cost barriers associated with PAP therapy. For instance, the Winnipeg Regional Health Authority offers co-payment options for CPAP therapy equipment, where new and replacement CPAP machines cost patients around US$ 500. This co-payment model is expected to save the health authority nearly US$ 4.9 million annually.
Similarly, the Ministry of Health's assistive devices program in Canada covers the costs associated with CPAP machines and related equipment. Organizations like Canadian Home Healthcare Inc. also provide financial assistance for acquiring CPAP devices. These initiatives, combined with the high prevalence of sleep disorders, are likely to bolster the PAP devices market in Canada during the forecast period.
In Mexico, the increasing rates of asthma and other respiratory conditions are driving the demand for PAP devices. According to a report published in January 2022 by the Annals of the American Thoracic Society, the prevalence of asthma among adults in Mexico is 2.85%, while it stands at 6.8% for children.
Hospitals such as San Jose Tec De Monterrey, Galenia Hospital, and San Angel Hospital are among those in Mexico that utilize PAP devices for treating sleep apnea disorders. The combination of rising asthma prevalence and an aging population is expected to significantly boost the demand for PAP devices in Mexico, thereby enhancing the market during the forecast period.
As awareness of respiratory diseases continues to grow, more individuals are seeking medical help for sleep-related issues. This increased awareness is leading to more frequent diagnoses of conditions like obstructive sleep apnea (OSA), which are often treated with CPAP or BiPAP machines. Public health campaigns by governments and medical institutions highlight the dangers of untreated sleep apnea, which can lead to serious health issues such as diabetes and cardiovascular diseases. Consequently, the demand for PAP devices is on the rise, driven by initiatives that promote early detection and treatment. The importance of sleep health is becoming more recognized, leading to a growing market for PAP devices as individuals seek ways to improve their sleep quality. For instance, the American Lung Association launched a campaign in November 2022 to raise awareness about COPD and the critical need for early diagnosis and improved quality of life for affected individuals. Sales of PAP devices are expected to surge as awareness of COPD and other respiratory conditions increases. ResMed's "Awaken Your Best" campaign aims to promote sleep treatment and tools for managing sleep disorders. Additionally, the "More than a Snore" campaign, initiated in February 2023, seeks to raise awareness about obstructive sleep apnea, a condition characterized by the collapse of the upper airway during sleep. In 2021, the National Center for Chronic Disease Prevention and Health Promotion provided a grant to the American Academy of Sleep Medicine to support this collaborative effort. Thus, the growing awareness of respiratory diseases is likely to create significant opportunities in the PAP devices market.
In terms of competition, key players in the positive airway pressure devices market include ICU Medical Inc, React Health (formerly 3B Medical, Inc), Fisher & Paykel Healthcare Corp Ltd, BPL Medical Technologies Pvt Ltd, Koninklijke Philips NV, ResMed Inc, Vyaire Medical Inc, Wellell Inc, Armstrong Medical Ltd, L?wenstein Medical UK Ltd., BMC Medical Co Ltd, Dragerwerk AG & Co KGaA, and Narang Medical Limited.
To compile the report on the positive airway pressure devices market, various primary and secondary sources were utilized, including Eurostat, Statistics Poland, the National Library of Medicine, the National Institute of Population and Social Security Research, the Australian Institute of Health and Welfare, Deloitte Access Economics, the National Center for Biotechnology Information (NCBI), the Lancet Journal, the United Nations Population Fund, the Pan American Health Organization, and the Centers for Disease Control and Prevention (CDC).